3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Colorectal Neoplasms
66
Pancreatic Neoplasms
35
Neuroblastoma
21
Neoplasm Metastasis
21
Neoplasms
16
Colonic Neoplasms
15
Stomach Neoplasms
14
Rectal Neoplasms
13
Esophageal Squamous Cell Carcinoma
9
Sarcoma, Ewing
8
Rhabdomyosarcoma
8
Small Cell Lung Carcinoma
7
Sarcoma
7
Ovarian Neoplasms
6
Lung Neoplasms
6
Cholangiocarcinoma
6
Esophageal Neoplasms
5
Breast Neoplasms
5
Adenocarcinoma Of Esophagus
5
Medulloblastoma
4
Endometrial Neoplasms
4
Biliary Tract Neoplasms
4
Adenocarcinoma
4
Recurrence
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Osteosarcoma
3
Locally Advanced Rectal Cancer
3
Glioma
3
Glioblastoma
3
Gastrointestinal Neoplasms
3
Interventions
pembrolizumab
96
Carboplatin
67
Paclitaxel
56
Cyclophosphamide
40
Capecitabine
30
Specimen Handling
28
sacituzumab govitecan
26
130-nm albumin-bound paclitaxel
25
Gemcitabine
22
Magnetic Resonance Spectroscopy
21
olaparib
20
Doxorubicin
20
Albumin-Bound Paclitaxel
20
Taxes
19
Biopsy
19
Drug Therapy
16
atezolizumab
14
Nivolumab
14
toripalimab
12
Radiotherapy
12
Epirubicin
12
durvalumab
11
Docetaxel
10
Cisplatin
10
Bevacizumab
10
eribulin
9
fludarabine
8
Standard of Care
7
Radiation
7
Injections
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Irinotecan
×
1 year
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled